Shields Carol L

Iris Melanoma Outcomes Based on the American Joint Committee on Cancer Classification (Eighth Edition) in 432 Patients.

The AJCC eighth edition classification provides prognostic stratification of iris melanoma.

Iris Microhemangiomatosis: Clinical, Fluorescein Angiography, and Optical Coherence Tomography Angiography Features in 14 Consecutive Patients.

Iris microhemangiomatosis is a rare ocular condition, often manifesting with spontaneous unilateral hyphema and/or secondary glaucoma. AS-IVFA confirms the diagnosis, and intervention with laser photocoagulation is necessary in only 9% of eyes.

Impact of uveal melanoma thickness on post-plaque radiotherapy outcomes in the prophylactic anti-vascular endothelial growth factor era in 1131 patients.

Compared with small and medium uveal melanoma, large uveal melanoma demonstrated greater 48-month risk for CME, shorter time to CME onset and greater development of NVI and NVG following plaque radiotherapy and prophylactic intravitreal bevacizumab.

Transscleral Cyclophotocoagulation for Glaucoma in the Setting of Uveal Melanoma.

Painful Glaucoma and Pseudohypopyon in a Child with Retinoblastoma.

Iris metastasis from systemic cancer in 104 patients: the 2014 Jerry A. Shields Lecture.

Metastatic tumors to the iris generally originate from primary malignancies in the breast, lung, or skin (melanoma). Despite successful ocular treatment, life prognosis is poor.